Heidelberg Pharma AG annual free cash flow
2022
2023
2024
2025
Heidelberg Pharma AG Free Cash Flow (FCF) History (HPHA)
Heidelberg Pharma AG reported −€31.7M in free cash flow for fiscal 2025, a decrease of €1.7M from the previous fiscal year, with a free cash flow margin of −2173.65%.
View full Heidelberg Pharma AG company overviewHeidelberg Pharma AG free cash flow by year
| Fiscal year | Period ended | Free cash flow | Change | Growth | FCF margin |
|---|---|---|---|---|---|
| 2025 | 2025-11-30 | −€31.7M | −€1.7M | — | −2173.65% |
| 2024 | 2024-11-30 | −€30.1M | €4.6M | — | −438.91% |
| 2023 | 2023-11-30 | −€34.6M | −€25.2M | — | −351.23% |
| 2022 | 2022-11-30 | −€9.5M | — | — | −51.20% |
Heidelberg Pharma AG quarterly free cash flow
Q1.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Free cash flow | Change | YoY growth | FCF margin |
|---|---|---|---|---|---|
| Q2 2026 | 2026-05-31 | −€1.1M | — | — | −24.60% |
| Q1 2026 | 2026-02-28 | −€6.3M | €2.4M | — | −206.34% |
| Q1 2025 | 2025-02-28 | −€8.7M | — | — | −685.25% |
Heidelberg Pharma AG free cash flow growth trends
Heidelberg Pharma AG's latest reported quarter, Q2 2026, generated −€1.1M in free cash flow.
About the metric
What free cash flow means
Free cash flow is the cash a company generates from operations after capital expenditures. Positive FCF can fund dividends, buybacks, debt repayment, or reinvestment; negative FCF means capital spending exceeded operating cash flow for that period.
Calculation and source
How free cash flow is calculated
TickerStat calculates free cash flow as reported operating cash flow minus capital expenditures. FCF margin equals free cash flow divided by revenue. Fiscal periods can differ from calendar years, so the tables include exact period-end dates.
Review Heidelberg Pharma AG source filings ↗Community posts
Heidelberg Pharma reports early myeloma responses and selects a development dose
Heidelberg Pharma ($HPHA) presented Phase 1 results for pamlectabart tismanitin, its experimental antibody-drug conjugate for relapsed or refractory multiple myeloma. Among 31 evaluable patients in dose cohorts five through nine, 13 respond ...
